Harmonic Discovery, a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, announces its launch today with $8 million in seed funding. The round was led by Innovation Endeavors with participation from Fifty Years, Y Combinator, Boom Capital, Caffeinated Capital and select angel investors. Dr. Joel Dudley, PhD, Partner at Innovation Endeavors, joins as a new Board Member.

Founded in 2021 and headquartered in New York City, Harmonic Discovery is a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology. The company's platform leverages multiple layers of kinase biology to design safer and more efficacious kinase therapeutics.